OP0108 LORECIVIVINT (SM04690), AN INTRA-ARTICULAR, SMALL-MOLECULE CLK2/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, PROVIDED CARTILAGE-PROTECTIVE EFFECTS IN AN ANIMAL MODEL OF POST-TRAUMATIC OA

• Published in: Annals of the rheumatic diseases Vol. 80; no. Suppl 1; p. 60
• Main Authors: Seo, T., Deshmukh, V., Yazici, Y.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2021
• Subjects: Animal models; Anterior cruciate ligament; Bone remodeling; Cartilage; Cartilage diseases; Chondrogenesis; Inflammation; Injection; Joint diseases; Knee; Meniscus; Osteoarthritis; Statistical analysis; Stockholders; Surgery; Trauma; Wnt protein
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2021-eular.2237

Background: Osteoarthritis (OA) is characterized by increased cartilage thinning, bone remodeling, and inflammation. Post-traumatic OA, which develops after acute direct trauma to the joints, accounts for approximately 12% of all OA cases. 1 Current therapeutic options focus on alleviating symptoms and pain rather than disease modification. Lorecivivint (LOR; SM04690), an intra-articular (IA), small-molecule CLK2/DYRK1A inhibitor that modulates the Wnt pathway, has been shown in animal studies to induce chondrogenesis, protect cartilage, and reduce inflammation and, thereby, improve joint health. 2 Objectives: A single IA LOR injection was evaluated in a rat model of knee instability to determine its protective and regenerative effects when injected at different timepoints after induction of post-traumatic OA. Methods: Knee instability/post-traumatic OA was surgically induced in rats by combining anterior cruciate ligament transection with partial medial meniscus transection (ACLT+pMMx). LOR (0.3 ug) or vehicle was injected into the IA space of the damaged knee at 2, 3, or 4 weeks after induction of OA. OA-induced (n=10/group) or sham-operated (surgery without ACLT+pMMx; n=5/group) rats were sacrificed at the injection timepoint (baseline) or 12 weeks following LOR/vehicle injection (study conclusion). Histological grades were evaluated using the summed OARSI scores (stage and grade of cartilage damage) 3 of the anterior and posterior medial femoral condyle (MFC) and medial tibial plateau (MTP). Weight distribution analysis was performed using an incapacitance meter at several timepoints. Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparison test. Results: ACLT+pMMx surgeries led to increased OARSI scores in rats compared with sham surgeries by 2 weeks. LOR treatment at Weeks 2, 3, and 4 led to significant decreases ( P <0.05) in total joint OARSI scores (Table 1) at the end of the study compared with vehicle treatment. Rats treated with LOR for 12 weeks and rats at injection baseline had similar OARSI scores, suggesting that LOR treatment arrested the progression of cartilage damage. Significant improvements ( P <0.05) were also observed in the weight distribution of LOR-treated rats in the 3- and 4-week groups at 6 and 12 weeks after their respective IA injections compared with vehicle-treated rats. Table 1. OARSI scores Week-2 injection Sham-operated (14 weeks after surgery) Baseline (BL ) (2 weeks after surgery) Vehicle (12 weeks after injection) LOR (12 weeks after injection) Total score 5.99 19.17 31.36 19.19 SEM 1.07 1.55 2.48 1.81 P value versus BL 0.9999 P value versus vehicle 0.0004 Week-3 injection Sham-operated (15 weeks after surgery) Baseline (BL ) (3 weeks after surgery) Vehicle (12 weeks after injection) LOR (12 weeks after injection) Total score 6.09 23.17 30.45 21.20 SEM 1.25 1.36 1.42 1.00 P value versus BL 0.4522 P value versus vehicle 0.0001 Week-4 injection Sham-operated (16 weeks after surgery) Baseline (BL ) (4 weeks after surgery) Vehicle (12 weeks after injection) LOR (12 weeks after injection) Total score 6.97 16.88 24.95 18.63 SEM 1.32 1.04 1.74 1.61 P value versus BL 0.6257 P value versus vehicle 0.0111 Conclusion: LOR exhibited cartilage-protective effects and slowed disease progression in the ACLT+pMMx model in vivo and, therefore, has potential as a structure-modifying treatment for OA. References: [1]Brown TD, et al. J Orthop Trauma . 2006. [2]Deshmukh V, et al. Osteoarthr Cartil. 2019. [3]Pritzker KPH, et al. Osteoarthr Cartil . 2006. Disclosure of Interests: Tim Seo Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Vishal Deshmukh Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Yusuf Yazici Shareholder of: Samumed, LLC, Employee of: Samumed, LLC